Changes in articular cartilage after intra-articular injections of methylprednisolone acetate in horses.
Eight mature horses with no prior signs of joint disease or history of intra-articular therapy were treated with 8 weekly intra-articular injections of methylprednisolone acetate. Treatments were given at a dose of 120 mg/joint into the right radiocarpal and intercarpal joints, with the left joints as untreated controls. Articular cartilage samples were obtained at necropsy 1, 4, and 8 weeks after the last injection. Compared with controls, cartilage from injected joints had a loss of hematoxylin basophilia and decreased intensity of staining in safranin O fast green dye. Chondrocyte necrosis and hypocellularity were observed in all samples of cartilage from treated joints. Proteoglycan content and its rate of synthesis were reduced. There was a progressive loss of proteoglycan content, whereas proteoglycan synthesis increased somewhat 4 and 8 weeks after treatment. Collagen content was unchanged, but its rate of synthesis was markedly inhibited. Collagen synthesis did not recover, but remained decreased at 5 to 15% of the values from untreated cartilage. Water percentage was increased, but fibronectin content was not significantly different. A single injection of methylprednisolone acetate was also given into the right metacarpophalangeal joints of 3 of the 8 horses in this group, with the left joints serving as untreated controls. Sixteen weeks after the treatment, cartilage of the treated joints had a loss of histochemical staining and proteoglycan content was reduced to 50% of control values. The mean rate of proteoglycan synthesis and mean fibronectin content were increased, but the differences were not statistically significant (P greater than 0.05). Other variables were essentially unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
Chunekamrai
S
S
Department of Equine Drug Testing and Research Program, New York State College of Veterinary Medicine, Cornell University, Ithaca 14853
Krook
L P
LP
Lust
G
G
Maylin
G A
GA
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002358:Cartilage, Articular / Q000032:analysis / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D003094:Collagen / Q000096:biosynthesis; D005353:Fibronectins / Q000032:analysis; D006736:Horses / Q000033:anatomy & histology*; D006909:Hydroxyproline / Q000032:analysis; D007270:Injections, Intra-Articular / Q000662:veterinary; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077555:Methylprednisolone Acetate; D011509:Proteoglycans / Q000096:biosynthesis; D013582:Synovial Fluid / Q000187:drug effects; D014783:Viscosity
D000893:Anti-Inflammatory Agents; D005353:Fibronectins; D011509:Proteoglycans; D000077555:Methylprednisolone Acetate; D003094:Collagen; D006909:Hydroxyproline; D008775:Methylprednisolone